The global prevalence of severe Clostridium difficile infection highlights the profound clinical significance of clostridial glucosylating toxins [1] [2] [3] [4] . Virulence is dependent on the autoactivation of a toxin cysteine protease [5] [6] [7] [8] [9] , which is promoted by the allosteric cofactor inositol hexakisphosphate (InsP 6 ) [10] [11] [12] [13] [14] [15] [16] [17] . Host mechanisms that protect against such exotoxins are poorly understood. It is increasingly appreciated that the pleiotropic functions attributed to nitric oxide (NO), including host immunity, are in large part mediated by S-nitrosylation of proteins 18, 19 . Here we show that C. difficile toxins are S-nitrosylated by the infected host and that S-nitrosylation attenuates virulence by inhibiting toxin self-cleavage and cell entry. Notably, InsP 6 -and inositol pyrophosphate (InsP 7 )-induced conformational changes in the toxin enabled host S-nitrosothiols to transnitrosylate the toxin catalytic cysteine, which forms part of a structurally conserved nitrosylation motif. Moreover, treatment with exogenous InsP 6 enhanced the therapeutic actions of oral S-nitrosothiols in mouse models of C. difficile infection. Allostery in bacterial proteins has thus been successfully exploited in the evolutionary development of nitrosothiol-based innate immunity and may provide an avenue to new therapeutic approaches.
C. difficile infection is the most prevalent cause of hospital-acquired infectious diarrhea and life-threatening colitis worldwide [1] [2] [3] [4] . Two large exotoxins, TcdA (308 kDa) and TcdB (270 kDa), are secreted from the majority of C. difficile strains that cause intestinal disease in humans [2] [3] [4] . Cellular internalization of these exotoxins is dependent on the cytosolic cofactor InsP 6 , which activates an autocatalytic cysteine protease domain (CPD) to facilitate toxin self-cleavage [9] [10] [11] [12] [13] [14] [15] [16] [17] . InsP 6 binds an allosteric site within the toxin CPD after its insertion into the plasma membrane. In a toxigenic disease model 20,21 , we found considerable cytopathology when we injected purified TcdA into ileal loops. TcdA induced marked intestinal mucosal damage, fluid secretion, neutrophil infiltration and transcription of proinflammatory genes, including Nos2 (encoding inducible nitric oxide synthase), Tnf (encoding tumor necrosis factor-α) and Il1b (encoding interleukin-1β) (Fig. 1a,b and Supplementary Fig. 1 ).
It has been suggested that Nos2-derived NO may limit C. difficile intoxication 20, 21 , but the molecular mechanism is not known. To explore a potential role for S-nitrosylation, we first assayed tissues for S-nitrosoglutathione (GSNO), a small endogenous S-nitrosothiol (SNO) that constitutes a major source of NO bioactivity in the respiratory 22 and gastrointestinal 23 tracts. Using HgCl 2 -coupled photolysis-chemiluminescence 22, 24 , we found a 12.1-fold increase in tissue GSNO concentration in TcdA versus buffer-injected loops (84 ± 29.1 versus 1,020 ± 475 nM mg −1 protein, respectively; P < 0.05; ± s.d.), which correlated with elevated Nos2 expression ( Fig. 1c and  Supplementary Fig. 1 ). The effects of GSNO are mediated primarily by targeted S-nitrosylation of proteins 18 . Immunofluorescence labeling of S-nitrosylated proteins (SNO-proteins) in tissue sections revealed high amounts of SNO-proteins within TcdA-exposed intestinal mucosa, and a similar SNO-protein accumulation was evident in biopsies from humans with active inflammation, suggesting pathophysiological relevance in human colitis (Fig. 1d) .
We characterized the toxin-induced S-nitrosoproteome using an unbiased cysteine saturation fluorescence proteomics assay 25 . Endogenous protein species identified here as showing higher levels of S-nitrosylation after toxin exposure included several species that are known targets of GSNO or other endogenous nitrosylases, including hemoglobin, heat shock, cytoskeletal and various cell signaling proteins. C. difficile infection is therefore associated with increases in tissue S-nitrosylation that probably reflect toxin-induced proinflammatory responses. Unexpectedly, TcdA itself was also consistently Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins identified as a molecular target of S-nitrosylation in inflamed tissues ( Fig. 1e and Supplementary Fig. 2) , and we confirmed this by a biotinswitch assay 26 that specifically labels Cys-NO adducts (Fig. 1e) .
Because there is no precedent for in situ S-nitrosylation of foreign proteins in host tissues, we established an in vitro model to examine the potential role of toxin S-nitrosylation. To recapitulate the epithelial SNO-protein accumulation observed during C. difficile infection, we transfected human Caco-2 colonocytes with a calciuminducible endothelial nitric oxide synthase (eNOS) construct (pCMV6-Nos3) to transiently raise cellular SNO expression 27 ( Fig. 1f,g and Supplementary Fig. 3a) . Both a biotin-switch assay and immunoblotting with an antibody to nitrosocysteine (SNO) showed that toxin recovered from toxin-exposed Nos3-transfected cells was S-nitrosylated and that S-nitrosylation was abolished by the membrane-permeable denitrosylating agent glutathione (GSH)-ethyl ester 27 (Fig. 1g) . Toxin-induced cell rounding and viability assays further showed that Nos3 transfection conferred significant protection against intoxication (Fig. 1h,i) . Moreover, toxin-induced UDP glucosylation of Rho GTPases 28 was markedly reduced in Nos3-transfected cells (Supplementary Fig. 3b,c) , consistent with a SNO-based mechanism of protection that inhibits the toxin's effects. Notably, this protection was significantly attenuated by GSH-ethyl ester and by (e) SNO proteomics showing in situ S-nitrosylated proteins from TcdA-exposed mouse ileum labeled with BODIPY FL maleimide 25 . MW, molecular weight. Inset, biotin-switch assay using a C-terminus specific antibody to TcdA. (f) SNO immunofluorescence in Nos3-transfected Caco-2 cells. High SNO-protein levels (green) co-localize with membrane ZO-1 (red). Scale bar, 10 µm. (g) Top, immunoblot showing eNOS and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression using IR-680 (red) and IR-800 (green) antibody labels, respectively, in vector-and Nos3-transfected Caco-2 cells. Bottom, immunoblots for TcdA-SNO and GAPDH (using IR-680 (red) and IR-800 (green) antibody labels, respectively), after immunoprecipitation with nitrosocysteine-specific antibodies in vector-and Nos3-transfected Caco-2 cells exposed to TcdA. TcdA-exposed cells were also treated with GSH-ethyl ester (GSH-EE) to remove NO groups from proteins (control). (h) TcdB-induced cell rounding in vector (left) versus Nos3 (right) transfected Caco-2 cells (71.1 ± 14.9% versus 26.5 ± 8.2%, respectively ± s.e.m., n = 3; P < 0.05, Mann-Whitney U test on ranks) (scale bar, 25 µm). (i) MTT assay for cytotoxicity in vector and Nos3-transfected Caco-2 cells exposed to 3.7 nM TcdB for 10 min. Controls included cells treated with GSH-EE and L-NAME (n = 3; error bars show s.e.m.; P < 0.05 compared to vector control-(*) and Nos3-(#) transfected cells, respectively; Mann-Whitney U test on ranks). (j) Immunoblots showing TcdA-SNO (top; labeled with IR-680) in human stool (n = 8) samples positive for TcdA (bottom; labeled with IR-800). TcdA-SNO was first immunoprecipitated from stool samples with a nitrosocysteine-specific antibody, and samples were then probed for TcdA. Presence of toxin in the stool was independently confirmed by ELISA and immunocytotoxicity assay 30 ( Supplementary Fig. 4 ). (Fig. 1i) . Mouse macrophages deficient in Nos2 were also more susceptible to toxin-induced glucosylation of Rac1 than were wildtype macrophages, which express elevated SNO 29 ( Supplementary  Fig. 3d ). Collectively, these data strongly suggest that toxin S-nitrosylation is a physiological mechanism of toxin inhibition.
l e t t e r s the eNOS inhibitor N-(G)-nitro-L-arginine-methyl ester (L-NAME)
To illustrate more directly that S-nitrosylation of the exotoxin has cytoprotective effects, we assessed the activity of S-nitrosylated toxin (toxin-SNO) in pure form. Purified TcdA was S-nitrosylated by treatment with GSNO, and synthesis of toxin-SNO was confirmed by biotinswitch assay (Supplementary Fig. 4a) . In vitro studies showed that toxin-SNO was significantly less cytotoxic compared with native toxin (Supplementary Fig. 4a ), and the protective effects of S-nitrosylation were abolished by GSH or dithiothreitol, which denitrosylated the toxin. TcdA-SNO was also significantly less cytotoxic in vivo as assayed in the toxigenic-loop model (Fig. 1a,b and Supplementary Fig. 1 ). The pathophysiological relevance of these data was strengthened by finding S-nitrosylated toxin in stool samples from humans with C. difficile infection and by an inverse relationship between levels of toxin-SNO and stool cytotoxicity, as determined by an ultrasensitive immunocytotoxicity assay 30 ( Fig. 1j and Supplementary Fig. 4b,c) . Thus, toxin S-nitrosylation seems to be both physiologically and functionally significant.
We sought to identify the S-nitrosylated residues responsible for inactivation of C. difficile toxins. Cysteine residues targeted by S-nitrosylation often conform to an acid-base consensus motif 31 . There are seven cysteine residues in TcdA and nine in TcdB, with four being conserved between the two toxins, including the catalytic cysteine [7] [8] [9] . Because the cysteine-histidine catalytic dyad conforms to a nitrosylation motif (see below) 18, 19 , we explored whether the toxin CPD is a preferred target for post-translational modification by GSNO. Crystal CPD structures of TcdA 15 and TcdB 9 show a well-defined catalytic cleft that is separated from a positively charged InsP 6 binding pocket abutting a β-hairpin fold (β-flap) (Fig. 2a and Supplementary  Fig. 5 ). In silico docking of GSNO to the toxin CPD structures predicted excellent alignment of the S-NO bond with the active site cysteine, which forms part of an exposed acid-base S-nitrosylation consensus motif that is structurally conserved amongst diverse microbial cysteine proteases, with glutamic acid and histidine residues juxtaposing the catalytic Cys: Cys700 in TcdA, Cys698 in TcdB, Cys3568 in Vibrio cholerae RTX toxin (RTX VC ) 12, 14 and Cys244 in gingipain R 32 (Fig. 2b,c and Supplementary Figs. 6 and 7) .
S-nitrosylation is often subject to allosteric regulation, and the prototypic example of hemoglobin provides a precedent where S-nitrosylation is modulated allosterically by both organic and inorganic phosphates, including InsP 6 . As a corollary, we hypothesized that InsP 6 binding to the CPD may regulate S-nitrosylation. Multiple lines of experimental evidence indeed confirmed this and suggest that the inositolphosphate-bound (that is, enzymatically active) form of the toxin is preferentially S-nitrosylated: (i) InsP 6 , and the more potent membrane-associated allosteric cofactor InsP 7 (ref. 33) , potentiated S-nitrosylation of TcdB by GSNO ( Fig. 2d and Supplementary  Fig. 8 ), and this effect was abolished by mutation of Cys698 to serine in TcdB (Fig. 2e) ; (ii) standard in vitro and real-time toxin cleavage assays showed that GSNO rapidly inhibited InsP 6 -induced toxin selfcleavage with a half-maximal inhibitory concentration (IC 50 ) of 12.9 ± 4.2 µM for TcdB ( Fig. 2f and Supplementary Fig. 9a) ; (iii) cysteinespecific cyanylation of C. difficile toxins using nitro-thiocyanobenzoic acid (NTCB)-based cleavage assays 34 identified TcdA Cys700 and TcdB Cys698 as principal S-nitrosylation sites ( Supplementary  Fig. 9b) ; (iv) S-nitrosylated CPD peptide fragments were identified by mass spectrometry only after InsP 6 and GSNO co-treatment ( Supplementary Fig. 10) ; (v) S-nitrosylation prevents the intracellular release of the toxin N-terminus effector domain (as evidenced by SNO-mediated inhibition of TcdB autocleavage; Supplementary  Fig. 11 ), which is dependent on inositolphosphate binding; Figure 2 Toxin S-nitrosylation is allosterically regulated by inositolphosphate. (a) N-terminus extended (cyan) CPD model for TcdB (based on 3PA8.pdb 9 and 3FZY.pdb 11 crystal structures), shows the β-flap (green) abutting the bound allosteric ligand InsP 6 (red). (b) Alignment of GSNO at CPD active site. Surface rendering of the TcdB CPD (3PA8.pdb) 9 showing the exposed S-nitrosylation consensus motif Glu743 (red)-Cys698 (yellow)-His653 (blue). GSNO docking shows the SNO group to be aligned with the catalytic Cys. (c) Crystal structures of TcdA (red) 15 , Vibrio cholerae RTX toxin (RTX VC ; blue) 11 and gingipain 33 (green). Structurally conserved residues, constituting a nitrosylation motif, are shown in the respective crystal structures. (d) Assessment of TcdB S-nitrosylation (using SNO-specific (IR800) and TcdB-specific (IR680) antibodies) and effect of InsP 6 (100 µM). DTT (1 mM) is used to remove NO from proteins (control). Supplementary  Fig. 8a ). SNO photolysis is used to eliminate SNO. InsP 6 binding to deoxygenated hemoglobin (Hb), which is inhibited by primary amide biotinylation, is provided as a positive control (n = 3; error bars show s.e.m.; *P < 0.05, # P < 0.05, compared to untreated TcdA and hemoglobin, respectively; Mann-Whitney U test on ranks). and (vi) GSNO treatment of toxin markedly inhibited InsP 6 binding to the CPD, and removal of SNO by photolysis restored InsP 6 binding (Fig. 2g) . This 'linkage' , incurred without major conformational change in the toxin (Supplementary Fig. 12 ), suggests that S-nitrosylation of the active-site cysteine regulates communication with the InsP 6 binding pocket, possibly by disordering the β-flap 12, 14, 15 . Taken together with earlier work 35 , these results raise the idea that crosstalk between inositolphosphate-and NO-based signaling may be a widespread phenomenon.
In control studies, we confirmed that cell membrane binding and in vitro UDP-glucosyltransferase activity of toxin-SNO was not diminished compared with native toxin (Supplementary Fig. 11c ) and that InsP 6 binding affinity for TcdA (K d of 62.6 ± 7.0 nM) is in close agreement with the activation constant (AC 50 ) for the CPD 15 ( Fig. 2g and Supplementary Fig. 8a) . Thus, GSNO attenuates the toxin by a dual orthosteric and allosteric mechanism of action: InsP 6 enables S-nitrosylation of the CPD, which, in turn, displaces the allosteric activator. Notably, the toxin cysteine protease structurally resembles the protease domain of caspases, which are subject to S-nitrosylation 19 . Inhibition of pro-caspase-3 by S-nitrosylation also entails both orthosteric (active site) and allosteric mechanisms 36 . Procaspase-3 is maintained in the S-nitrosylated and inactive state in the mitochondria but not in the cytosol 37 . Our new findings (Fig. 1d,f) suggest that membrane compartments may provide privileged access to allosteric cofactors 33 that may act as determinants of subcellular S-nitrosylation.
Consensus motifs for S-nitrosylation may influence the nucleophilicity of thiol or the binding of nitrosylating agents 18, 31, 37 . Disruption of the CPD-containing motif for S-nitrosylation (Fig. 2b,c and Supplementary Figs. 6 and 7) by mutagenesis of Glu743 to alanine diminished the ability of GSNO to transnitrosylate TcdB (Fig. 3a) . By contrast, mutation of the catalytic His653 to alanine in TcdB had little effect on S-nitrosylation (Fig. 3a) . This observation is consistent with the unusually large distances (>6Å) between the catalytic cysteines and histidines in toxin CPDs 15 . Rather than increasing nucleophilicity of the catalytic cysteine, His653 is likely to play a part in substrate orientation, assisted by a catalytic aspartic acid that may stabilize the histidine imidazolium ring (Fig. 3b and  Supplementary Figs. 13 and 14) . Mutagenesis of His653 to alanine in TcdB confirmed its role in catalytic activity (Fig. 3c) . Cysteine and histidine CPD mutants were also significantly less cytotoxic than wild-type protein, confirming previous reports 7, 13, 16 . Glu743 in the cysteine protease active site is predicted to modulate cysteine thiolate reactivity (in addition to docking of GSNO) via hydrogen-bonding interactions ( Fig. 3b and Supplementary Fig. 14) . Mutagenesis of Glu743 in TcdB greatly enhanced toxin self-cleavage in the presence of inositolphosphate cofactor (Fig. 3c,d) . Thus, Glu743 regulates the allosteric switch 38 induced by InsP 6 on the one hand (which may restrict toxin self-cleavage in the gut lumen where InsP 6 is derived from dietary sources), and facilitates efficient S-nitrosylation on the other hand.
Metronidazole and vancomycin can effectively treat C. difficile infection, but the association of these drugs with high relapse rates represents a major health problem [1] [2] [3] [4] . These considerations necessitate the development of alternative therapeutic strategies. The observation that S-nitrosylation inhibits toxin self-cleavage and that GSNO probably serves as the endogenous S-nitrosylating agent prompted us to test whether GSNO can be exploited therapeutically to protect against C. difficile infection. Exogenous GSNO efficiently S-nitrosylated epithelial cell proteins in culture (Fig. 4a) and protected against Tcd cytotoxicity (IC 50 of 57.9 ± 13.7 and 46.3 ± 7.1 µM for TcdA and TcdB, respectively) (Fig. 4b) . Inhibition of toxin activity by GSNO was reversed by denitrosylating agents (GSH or dithiothreitol), and cytoprotection by GSNO was greatly enhanced by inositolphosphate cofactor, which lowered the IC 50 into the low micromolar range (Fig. 4b  and Supplementary Fig. 15a ). Using the toxigenic-loop model, Figs. 7 and 14) . The substrate domain (autocleavage site) is shown in turquoise (inset) and in red (top), where it bridges TcdB glucosyltransferase (GT) and cysteine protease (blue) domains, as shown in the combined crystal l e t t e r s 1 1 4 0 VOLUME 17 | NUMBER 9 | SEPTEMBER 2011 nature medicine we confirmed that exogenous GSNO injected intralumenally reduced TcdA-induced inflammation, fluid secretion and histopathology (Fig. 4c,d and Supplementary Fig. 15b ). In addition, intraluminal InsP 6 potentiated the therapeutic actions of exogenous S-nitrosothiol in vivo (Fig. 4c,d) . We also tested the therapeutic efficacy of GSNO in a mouse infectious disease model that closely mimics the human disease 1 . Kaplan-Meier survival plots of infected mice showed a survival benefit of oral GSNO that was markedly enhanced by oral InsP 6 (Fig. 4e) . Direct delivery of GSNO and InsP 6 into the cecum produced an even greater therapeutic effect (84.4 ± 4.1% survival with GSNO and InsP 6 versus 50.0 ± 11.7% survival with GSNO, respectively; P < 0.05; ± s.e.m.) (Fig. 4e,f) . These combined benefits of GSNO and InsP 6 identify the toxin as a primary locus of GSNO action and may thus form the basis of a new treatment for unchecked C. difficile infection.
S-nitrosylation is already known to suppress parasitic and viral pathogenesis by inhibiting cysteine proteases 39 . However, host S-nitrosylation has not previously been shown to directly inhibit microbial exotoxin activity, and the dual protective mechanism identified here (catalytic-site inhibition and displacement of allosteric activator) is novel (Fig. 4g) . Given the recent descriptions of a large number of microbial proteases (multifunctional autoprocessing RTX toxins (CPD MARTX ) and CPD adh , a cysteine peptidase family homologous to MARTX) 5, 8 that show close structural similarly to the C. difficile toxins and probably require an active-site cysteine for host cell adhesion and entry, S-nitrosylation may represent a common host defense mechanism. This notion is supported by similar GSNO docking results to the CPD active site in C. difficile toxins and RTX VC , a member of the MARTX family. Our results may be viewed in a broader context in which hyper-and hyponitrosylation of specific proteins represent disease-modifying events 18, 37 . A major challenge in NO therapeutics is to selectively and specifically control the nitrosylation state of proteins that are identified with pathophysiology. Previous studies have indicated that allosteric mechanisms may be crucial in governing NO specificity 18, 40 , and we now provide a potential therapeutic context for this principle by showing that allosteric modulation of S-nitrosylation can be used to treat C. difficile infection in mice. More generally, improved understanding of allosteric mechanisms may suggest new therapeutic approaches to regulating molecular targets of nitrosylation.
MeTHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Generation, treatment and testing of native and recombinant C. difficile toxins. Purification of TcdA and TcdB from toxigenic C. difficile strain VPI10463 was performed and tested for cytotoxicity as previously described 2 . Toxin purity was assessed by SDS-PAGE, confirming molecular masses for TcdA and TcdB as 308 kDa and 270 kDa, respectively. Full-length, bioactive recombinant TcdB was expressed in a Bacillus megaterium system. To test S-nitrosylation effects on intracellular autocleavage efficiency in cells, we generated several recombinant TcdB proteins, including the point mutations Cys698Ser (catalytic cysteine), His653Ala (catalytic histidine), Glu743Ala (glutamic acid forming part of the S-nitrosylation motif) and glucosyltransferase-domain substrate binding residues (Trp102Ala and Asp288Asn) that essentially abolish TcdB toxicity.
ONLINe MeTHOdS
In vitro and BiaCore toxin cleavage assays. Autocleavage of 1 µg TcdA and TcdB holotoxins and recombinant native and mutant TcdB was performed in 25 µl 20 mM Tris-HCl, 150 mM NaCl (pH 7.4) with and without InsP 6 , GSNO, GSH or DTT for 10 min to overnight at 37 °C as described 7 .
Toxin exposure of cell lines. Caco-2 cells transiently transfected with pCMV6-Nos3 (sequence identical to NM_000603) or control vector pCMV6 were seeded in six-well or 96-well tissue culture plates at a concentration of 5 × 10 4 cells per well in 100 µl of medium. Amaxa-Nucleofector-based electroporations were performed according to the manufacturer's instructions (Lonza) and typically resulted in 50% transfection rates (Supplementary Fig. 3a) . After 48 h, cells were treated to facilitate calcium influx and 12 h later intoxicated with TcdA or TcdB (dose range of 0.4-40 nM) for 3-15 min, and cells were then washed three times with fresh medium. For short-term experiments testing Rac1 glucosylation levels, cells were intoxicated for 10-120 min, and cell lysates were probed with Rac23A8 (total Rac1) and Rac102 (nonglucosylated) antibodies. For acute cellular autocleavage assays, transfected cells were intoxicated with recombinant avirulent TcdB (20 nM) for 3 min before collection of cell lysates. For MTT assays, cells were cultured for a minimum of 48 h after toxin exposure.
Studies in humans with C. difficile and stool cytotoxicity assay. Institutional Review Board Approval at University of Texas Medical Branch was provided with informed consent for analysis of coded stool samples from subjects with antibiotic-associated diarrhea being investigated for C. difficile infection. Eight unformed stool specimens tested positive for TcdA by western blotting (A1H3) and for stool cytotoxicity by immunocytotoxicity assay 30 . For the immunocytotoxicity assay, stool samples were diluted in PBS (50-fold) and filtered through a 0.2-µm membrane. Samples were mixed with A1H3 (2 µg ml −1 final concentration) and mRG1 cells (2 × 10 4 well) before adding to xCELLigence system dynamic monitoring E plates. A control set of wells included neutralizing goat antibody (1 in 1,000; TechLab) to specifically block TcdA activity. Cell indexes of wells were monitored and a positive sample was defined as a cell index value (in the absence of antisera) equal or less than 50% of that in the presence of antisera. TcdA S-nitrosylation was investigated by SNO-specific antibody immunoprecipitation and detection with A1H3 antibody 30 .
Exposure of mouse ileal loops to TcdA. All procedures were performed with Institutional Animal Care and Use Committee approval at University of Texas Medical Branch, Tufts University Cummings School of Veterinary Medicine and University of California-Los Angeles, and in accordance with US National Institute of Health guidelines for use of live animals. Cd-1 mice (10-week-old males; Charles River Labs) were fasted overnight. Ileal loops were ligated in anesthetized mice via laparotomy and injected with 0.15 ml of purified TcdA, TcdA-SNO or TcdA-NEM (10 µg) or buffer as previously described 2, 20 . Test mice were additionally pretreated with GSNO, InsP 6 or GSNO-InsP 6 (0.1 ml; 10 mg per kg body weight ± InsP 6 1 mM) for 15 min before inoculation of TcdA. Four hours after TcdA administration, mice were killed, and fluid secretion was determined as the loop weight (100 mg)-to-length (cm) ratio. Fullthickness loops were frozen in liquid nitrogen or fixed in 10% formalin in PBS (pH 7.2) for 24 h and embedded in paraffin by routine procedures. Histological severity of enteritis was evaluated by assessing epithelial cell necrosis, hemorrhagic congestion and edema of the mucosa and neutrophil margination and tissue infiltration 2, 20 .
Mouse C. difficile infection model. A conventional mouse model of antibiotic-induced C. difficile infection that closely resembles the spectrum of disease manifest in humans was used as described 1 .
Statistical analyses.
Results are presented as mean values ± s.e.m. Statistical significance was determined using t test, Mann-Whitney U test on ranks and ANOVA on ranks with SigmaStat software. n = 3 unless otherwise stated; P < 0.05 was considered statistically significant. Additional methods. Detailed methodology is described in the Supplementary Methods.
